Clovis Oncology (CLVS) Stock Analysis

What Clovis Oncology does

Clovis Oncology, Inc. is a biopharmaceutical firm dedicated to the acquisition, development, and commercialization of oncology therapeutics across the United States, Europe, and globally. Within the United States, their flagship product is Rubraca (rucaparib), an orally administered small molecule that inhibits poly ADP-ribose polymerase (PARP), indicated for recurring epithelial ovarian, fallopian tube, or primary peritoneal malignancies, as well as for metastatic castration-resistant prostate cancer. European markets see Rubraca approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline further includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFRa/ß), and fibroblast growth factor receptors (FGFR 1-3), and FAP-2286, an experimental peptide-targeted radionuclide therapy and diagnostic agent specifically designed to target fibroblast activation protein. Rubraca's distribution model relies on a select network of specialty distributors and pharmacies, which in turn supply the medication to patients and medical professionals. The company maintains licensing agreements with prominent entities such as Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical partnership with Bristol Myers Squibb Company, and a strategic alliance with Foundation Medicine, Inc. Established in 2009, Clovis Oncology is headquartered in Boulder, Colorado. However, on December 11, 2022, Clovis Oncology, Inc., along with its affiliated entities, initiated voluntary Chapter 11 reorganization proceedings in the U.S. Bankruptcy Court for the District of Delaware.

Key metrics

ETFs linked to CLVS

Broad-market and Healthcare sector ETFs an investor holding Clovis Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CLVS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Clovis Oncology?

Clovis Oncology trades under the ticker CLVS on NASDAQ.

Which exchange is CLVS listed on?

CLVS is listed on NASDAQ.

What sector does Clovis Oncology operate in?

Clovis Oncology is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CLVS in a portfolio?

PortView shows CLVS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.